Compare CRWS & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRWS | TVRD |
|---|---|---|
| Founded | 1957 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 27.5M |
| IPO Year | 1994 | 2013 |
| Metric | CRWS | TVRD |
|---|---|---|
| Price | $2.68 | $1.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.50 |
| AVG Volume (30 Days) | 114.6K | ★ 128.2K |
| Earning Date | 02-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 11.49% | N/A |
| EPS Growth | ★ 118.89 | 79.01 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $70,270,000.00 | $911,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.88 | ★ N/A |
| Revenue Growth | 6.51 | ★ 959.30 |
| 52 Week Low | $2.35 | $1.50 |
| 52 Week High | $3.14 | $43.65 |
| Indicator | CRWS | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 43.61 |
| Support Level | $2.69 | $1.72 |
| Resistance Level | $2.91 | $2.04 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 12.16 | 44.48 |
Crown Crafts Inc operates in the infant and toddler products segment of the consumer products industry through its wholly-owned subsidiaries. The infant and toddler products segment consists of infant and toddler bedding, bibs, soft bath products, disposable products, and accessories. The company serves a diverse range of customers including mass merchants, mid-tier retailers, juvenile specialty stores, value channel stores, grocery and drug stores, restaurants, internet accounts, wholesale clubs, and internet-based retailers. The company's brands include NoJo, Neat Solutions, Sassy, and Carousel. Its products are marketed under a variety of company-owned trademarks, under trademarks licensed from others, and as private-label goods.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.